Researchers demonstrate improved remission rates in leukemia with engineered CAR T-cells, suggesting enhanced treatment potential.
Researchers used a unique base-editing strategy to engineer chimeric-antigen receptor (CAR) T cells that engraft in the host and remain invisible to remaining antibody drugs. Of the 11 patients with T-cell acute lymphoblastic leukemia who received these BE-CAR7 T cells, all had complete morphogenic remission after 28 days, 82% underwent stem-cell transplantation, and 64% remain in remission 3 to 36 months after treatment.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: